Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction

Heart Failure

Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF

Eur J Heart Fail

Malgie J, Wilde MI, Koudstaal S, Denham R, da Fonseca CA, Swart HP, van Ofwegen CEE, Yilmaz A, Pisters R, Linssen GCM, Faber N, van Heerebeek L, van de Swaluw JEC, de Boer RA, Brunner-La Rocca HP, Brugts JJ

doi: 10.1002/ejhf.70006

Heart Failure

One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge

JAMA Cardiol

Greene SJ, Xu H, Chiswell K, Felker GM, Lewsey SC, Divanji PH, Goertz HP, Heitner SB, Shreay S, Pandey A, Yancy CW, Butler J, Fonarow GC

doi: 10.1001/jamacardio.2025.5339

Heart FailureTherapy and Intervention

Clinical Application of Guideline-Directed Medical Therapy in TAVR Patients With Heart Failure and Reduced Ejection Fraction

JACC Cardiovasc Interv

Kobari Y, Maznyczka A, Khokhar AA, Sørensen LM, Lulic D, Bieliauskas G, Raja AA, Ersbøll MK, Rossing K, Gustafsson F, Køber L, Prendergast B, Fosbøl E, De Backer O

doi: 10.1016/j.jcin.2025.10.050

Heart Failure

Impact of contemporary guideline-directed medical therapy on secondary mitral and tricuspid regurgitation in heart failure with reduced ejection fraction

Eur J Heart Fail

Naser JA, Rahme SJ, Castrichini M, Ibrahim H, Scott CG, Kennedy AM, Eleid MF, Nkomo VT, Foley DA, McKie PM, Borlaug BA, Pislaru SV, Lin G

doi: 10.1093/ejhf/xuag047

Heart Failure

Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction

JACC Heart Fail

Siqueira SRO, Pabon MA, Vaduganathan M, Claggett BL, Lam CSP, Kosiborod MN, de Boer RA, Shah SJ, Fang JC, Desai AS, Jhund PS, Inzucchi SE, Martinez F, Hernandez AF, Petersson M, McMurray JJV, Solomon SD, Vardeny O

doi: 10.1016/j.jchf.2025.102585

Heart Failure

Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure With Improved Ejection Fraction

J Am Coll Cardiol

Min KH, Go AS, Lee K, Parikh RV, Horiuchi KM, Ambrosy AP, Tan TC, Srikanth K, Hamilton SA, Svetlichnaya J, Solomon SD, Inciardi RM, Vardeny O, Vasti E, Sandhu AT, Ku IA, Adatya S, Bhatt AS

doi: 10.1016/j.jacc.2025.05.040

Heart Failure

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial

Eur J Heart Fail

Mentz RJ, Butler J, McMullan CJ, Wojdyla DM, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Zannad F, VICTOR Study Group

doi: 10.1002/ejhf.70033

Heart Failure

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial

Eur Heart J

Butler J, Fioretti F, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Teixeira PP, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F

doi: 10.1093/eurheartj/ehaf655

Heart Failure

Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF

Circ Heart Fail

Butt JH, Henderson AD, Jhund PS, Claggett BL, Desai AS, Borentain M, Rohwedder K, Dayoub R, De Sanctis Y, Lam CSP, Senni M, Shah SJ, Voors AA, Bauersachs J, Fonseca C, Linssen GCM, Petrie MC, Schou M, Verma S, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV

doi: 10.1161/CIRCHEARTFAILURE.125.013201

Related content

Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF

One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge

Clinical Application of Guideline-Directed Medical Therapy in TAVR Patients With Heart Failure and Reduced Ejection Fraction

Impact of contemporary guideline-directed medical therapy on secondary mitral and tricuspid regurgitation in heart failure with reduced ejection fraction

Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction

Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure With Improved Ejection Fraction

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial

Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF